Monitoring Your Health and Looking Forward
At a Glance
For people with FSGS, achieving remission—especially a major reduction in urine protein—is linked with a better kidney outlook. Regular checks of urine protein, kidney filtering, blood pressure, and potassium guide care, while transplant recurrence risk depends on the FSGS type.
Living with Focal Segmental Glomerulosclerosis (FSGS) is a marathon, not a sprint. While the initial diagnosis can be frightening, long-term health is largely defined by how well the disease responds to treatment and how consistently you and your care team manage your kidney health day-to-day.
The Power of Remission
The single most important predictor of your long-term kidney health is achieving remission [1]. Remission means that the amount of protein leaking into your urine (proteinuria) has dropped significantly.
Doctors generally use two levels of remission to track progress [2][3]:
- Complete Remission: Your protein levels drop to near-normal levels—often defined as a Urine Protein-to-Creatinine Ratio (UPCR) of less than 0.3 g/g [2].
- Partial Remission: Your protein levels drop by at least 50% from where they started and stay roughly within the 0.3 to 3.5 g/g range [2].
Even if you do not reach complete remission, achieving a partial remission is a major victory. Research shows that patients in both complete and partial remission have a much lower risk of their disease progressing to End-Stage Renal Disease (ESRD) compared to those whose protein levels remain high [4][5]. However, remission does not guarantee stable eGFR, and the meaning of partial remission depends on the cause and starting kidney function; proteinuria and eGFR must be followed together.
Daily Management Strategies
Managing FSGS at home focuses on reducing the stress on your kidneys and monitoring for changes.
- Blood Pressure Control: High blood pressure acts like a “pressure cooker” for your kidney filters [6]. Contemporary KDIGO blood-pressure guidance uses a standardized office systolic target below 120 mmHg when tolerated for many adults with CKD, while home measurements may use different targets. Your doctor will personalize this goal for you [7].
- Sodium (Salt) Intake: Eating less salt helps your body hold onto less fluid, which reduces swelling (edema) and lowers blood pressure [6]. Aim for a “sodium-conscious” diet by avoiding processed foods and not adding extra salt at the table.
- Monitoring: Your doctor will likely request regular blood and urine tests to monitor your eGFR (a measure of how well your kidneys are filtering) and your protein levels [5]. If you are on RAAS blockade (ACE inhibitors or ARBs), they will also check your potassium levels frequently, as these drugs can sometimes cause potassium to rise [8][9].
Prognosis and Progression
“Prognosis” is a medical term for the likely course of a disease. In FSGS, several factors influence whether the disease will stay stable or lead to kidney failure [1]:
- Baseline Function: How well your kidneys were working at the time of diagnosis [1].
- The Biopsy: The amount of existing scarring seen on your biopsy (interstitial fibrosis) can provide clues about how much “reserve” your kidneys have left [1].
- Response to Treatment: As mentioned, how much your protein levels drop during treatment is the strongest sign of a positive outlook [5].
Looking Toward Transplantation
If FSGS eventually leads to kidney failure, a kidney transplant is often the best option for restoring health and quality of life. However, there is a crucial distinction between the different types of FSGS when it comes to a new kidney [10]:
- Primary FSGS: Because this type is thought to be caused by a factor in the blood, it can return (recur) in the new kidney. The recurrence risk varies with diagnostic certainty, age, and prior transplants, but can range from 30% to 40% (and may be higher in children) [11][12]. If it does recur, it often happens early [13].
- Genetic and Secondary FSGS: The risk of these forms returning in a new kidney is considered very low, though not absolute zero [11][10]. This is because the original cause—such as an intrinsic genetic mutation or a structural stressor—is usually not present in the donor kidney, although persistent systemic causes like obesity can still injure an allograft.
Knowing your specific “type” of FSGS early on helps you and your transplant team create a monitoring plan to catch any recurrence early, when it is most treatable [14].
Common questions in this guide
What does remission mean in FSGS?
How is FSGS monitored over time?
What blood pressure target is appropriate for someone with FSGS?
What factors affect the prognosis of FSGS?
Can FSGS return after a kidney transplant?
What can I do day to day to manage FSGS?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Focal segmental glomerulosclerosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my latest tests, am I in complete remission, partial remission, or neither?
- 2.What specific blood pressure target is right for me, given my age and the amount of protein I am losing?
- 3.What is my current eGFR slope, and what does it tell us about how quickly my kidney function is changing?
- 4.If I need a transplant in the future, how does my specific 'type' of FSGS (primary vs. secondary/genetic) affect the risk of the disease returning?
- 5.How often should we be checking my potassium levels and kidney function while I am on blood pressure medications?
References
References (14)
- 1
Clinical presentation, treatment and outcome of focal segmental glomerulosclerosis in Far North Queensland Australian adults.
Greenwood AM, Gunnarsson R, Neuen BL, et al.
Nephrology (Carlton, Vic.) 2017; (22(7)):520-530 doi:10.1111/nep.12816.
PMID: 27170059 - 2
An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis.
Troost JP, Trachtman H, Nachman PH, et al.
Clinical journal of the American Society of Nephrology : CJASN 2018; (13(3)):414-421 doi:10.2215/CJN.04780517.
PMID: 29167190 - 3
The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: A systematic review and meta-analysis of 77 case-reports and case-series.
Kashgary A, Sontrop JM, Li L, et al.
BMC nephrology 2016; (17(1)):104 doi:10.1186/s12882-016-0322-7.
PMID: 27473582 - 4
Renal survival and treatment of adult patients with Primary Focal Segmental glomerulosclerosis: A historical cohort study of the National Greek Registry.
Marinaki S, Kompotiatis P, Michelakis I, et al.
PloS one 2024; (19(12)):e0315124 doi:10.1371/journal.pone.0315124.
PMID: 39693288 - 5
Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis.
Troost JP, Trachtman H, Spino C, et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2021; (77(2)):216-225 doi:10.1053/j.ajkd.2020.04.014.
PMID: 32791086 - 6
Chronic kidney disease.
Kalantar-Zadeh K, Jafar TH, Nitsch D, et al.
Lancet (London, England) 2021; (398(10302)):786-802 doi:10.1016/S0140-6736(21)00519-5.
PMID: 34175022 - 7
Adherence to the Kidney Disease: Improving Global Outcomes CKD Guideline in Nephrology Practice Across Countries.
Stengel B, Muenz D, Tu C, et al.
Kidney international reports 2021; (6(2)):437-448 doi:10.1016/j.ekir.2020.11.039.
PMID: 33615069 - 8
Clinical Management of Hyperkalemia.
Palmer BF, Carrero JJ, Clegg DJ, et al.
Mayo Clinic proceedings 2021; (96(3)):744-762 doi:10.1016/j.mayocp.2020.06.014.
PMID: 33160639 - 9
Optimizing renin-angiotensin-aldosterone inhibition in advanced chronic kidney disease: balancing benefits and risks.
Spencer S, Bhandari S
Current opinion in nephrology and hypertension 2025; (34(6)):469-476 doi:10.1097/MNH.0000000000001076.
PMID: 40207744 - 10
Recurrence and Treatment after Renal Transplantation in Children with FSGS.
Kang HG, Ha IS, Cheong HI
BioMed research international 2016; (2016()):6832971 doi:10.1155/2016/6832971.
PMID: 27213154 - 11
Incidence and risk factors for recurrent focal segmental glomerulosclerosis after kidney transplantation: a meta-analysis.
Bai J, Zhang T, Wang Y, et al.
Renal failure 2023; (45(1)):2201341 doi:10.1080/0886022X.2023.2201341.
PMID: 37070350 - 12
Incidence, risk factors, and outcomes of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: A systematic review and meta-analysis.
Bai J, Yin X, Li J, et al.
Clinical transplantation 2023; (37(11)):e15119 doi:10.1111/ctr.15119.
PMID: 37725070 - 13
Therapeutic Options for Recurrence of Primary Focal Segmental Glomerulonephritis (FSGS) in the Renal Allograft: Single-Center Experience.
Vallianou K, Marinaki S, Skalioti C, et al.
Journal of clinical medicine 2021; (10(3)) doi:10.3390/jcm10030373.
PMID: 33498160 - 14
Kidney Transplantation for Focal Segmental Glomerulosclerosis: Can We Prevent Its Recurrence? Personal Experience and Literature Review.
Naciri Bennani H, Elimby L, Terrec F, et al.
Journal of clinical medicine 2021; (11(1)) doi:10.3390/jcm11010093.
PMID: 35011834
This page is for informational purposes only and does not constitute medical advice. Your nephrologist and transplant team can interpret your results and recommend monitoring for your specific situation.